Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil, oteracil potassium) for gastric cancer

Gastric Cancer

Volumn 7, Issue 2, 2004, Pages 104-109

  Kinoshita, Taira ^a   Nashimoto, Atsushi ^b   Yamamura, Yoshitaka ^c   Okamura, Takeshi ^d   Sasako, Mitsuru ^e   Sakamoto, Junichi ^f   Kojima, Hiroshi ^f   Hiratsuka, Masahiro ^g   Arai, Kuniyoshi ^h   Sairenji, Motonori ⁱ   Fukushima, Norimasa ^j   Kimura, Hironobu ^k   Nakajima, Toshifusa ^l  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b NIIGATA CANCER CENTER HOSPITAL   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

^d NATIONAL KYUSHU CANCER CENTER   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL   (Japan)

^f AICHI PREFECTURAL UNIVERSITY   (Japan)

^g OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^h TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

ⁱ KANAGAWA CANCER CENTER   (Japan)

^j Yamagata Prefectural Central Hospital   (Japan)

^k TOYAMA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^l CANCER INSTITUTE HOSPITAL   (Japan)

more..

Author keywords

Adjuvant chemotherapy; Feasibility study; Gastric cancer; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; DIARRHEA; DRUG EFFECT; FATIGUE; FEASIBILITY STUDY; FEMALE; GASTRECTOMY; HUMAN; HYPERBILIRUBINEMIA; LEUKOPENIA; MALE; NAUSEA; NEUTROPENIA; POSTOPERATIVE CARE; PRIORITY JOURNAL; STOMACH CANCER; STOMATITIS;

EID: 3142628182     PISSN: 14363291     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10120-004-0278-3     Document Type: Article

References (10)

1. Maruyama K, Okabayashi K, Kinoshita T. Progress in gastric cancer surgery in Japan and its limits of radicality. World J Surg 1987;11:418-25.
2. Nakajima T, Ohta K, Ohyama S, Hamashima N. Meta-analysis of adjuvant chemotherapy trial for gastric cancer at the Cancer Institute Hospital, Tokyo. In: Nakajima T, Yamaguchi T. editors. Multimodality therapy for gastric cancer. Heidelberg Berlin New York Tokyo: Springer-Verlag; 1988. pp. 27-31.
3. Hermans J, Bonenkamp JJ, Boon MC, Bunt AM, Ohyama S, Sasako M, et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 1993;11:1441-47.
4. Nakajima T. Gastric cancer treatment guidelines in Japan. Gastric Cancer 2002;5:1-5.
5. Sugimachi K, Maehara Y, Horikoshi N, Shimada Y, Sakata Y, Miyachi Y, et al. An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. Oncology 1999;57:202-10.
6. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-04 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998;34:1715-20.
7. Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 2000;58:191-7.
8. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma. 2nd English Ed. Gastric Cancer 1998;1:10-24.
9. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-30.
10. Maehara Y. S-1 in gastric cancer: a comprehensive review. Gastric Cancer 2003;6 (Suppl 1):2-8.